Seres Therapeutics Inc (NASDAQ:MCRB) was the target of a significant decline in short interest in June. As of June 30th, there was short interest totalling 4,328,500 shares, a decline of 35.4% from the May 30th total of 6,701,700 shares. Based on an average daily volume of 519,100 shares, the days-to-cover ratio is currently 8.3 days. Approximately 20.9% of the shares of the stock are sold short.

Seres Therapeutics stock traded down $0.09 during mid-day trading on Friday, reaching $2.90. 41,669 shares of the company’s stock traded hands, compared to its average volume of 1,263,412. The stock has a market capitalization of $122.89 million, a P/E ratio of -1.18 and a beta of 2.04. The firm’s 50 day moving average price is $3.14. Seres Therapeutics has a 12-month low of $2.02 and a 12-month high of $9.26.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.12). The company had revenue of $7.32 million for the quarter, compared to the consensus estimate of $8.61 million. On average, research analysts anticipate that Seres Therapeutics will post -1.75 earnings per share for the current year.

Several equities analysts have recently commented on MCRB shares. Chardan Capital reissued a “buy” rating on shares of Seres Therapeutics in a report on Monday, June 17th. HC Wainwright reissued a “buy” rating on shares of Ballard Power Systems in a report on Friday, May 3rd. Cantor Fitzgerald reissued a “buy” rating and issued a $15.00 target price on shares of Foamix Pharmaceuticals in a report on Tuesday, May 7th. Jefferies Financial Group lowered their target price on shares of Seres Therapeutics from $6.00 to $4.00 and set a “hold” rating on the stock in a report on Monday, July 1st. Finally, ValuEngine downgraded shares of Yext from a “strong-buy” rating to a “buy” rating in a report on Friday, May 10th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. Seres Therapeutics currently has an average rating of “Hold” and an average price target of $10.25.

In other news, Director Noubar Afeyan purchased 8,888,888 shares of the stock in a transaction on Tuesday, June 18th. The shares were acquired at an average price of $2.25 per share, with a total value of $19,999,998.00. Following the completion of the acquisition, the director now directly owns 15,141 shares of the company’s stock, valued at $34,067.25. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 37.00% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA raised its stake in Seres Therapeutics by 945.5% during the first quarter. BNP Paribas Arbitrage SA now owns 4,339 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 3,924 shares in the last quarter. Great West Life Assurance Co. Can purchased a new stake in Seres Therapeutics during the fourth quarter valued at $30,000. Two Sigma Investments LP bought a new position in Seres Therapeutics during the fourth quarter valued at $82,000. Rhumbline Advisers increased its position in Seres Therapeutics by 48.8% during the fourth quarter. Rhumbline Advisers now owns 27,136 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 8,895 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale increased its position in Seres Therapeutics by 21.5% during the first quarter. DekaBank Deutsche Girozentrale now owns 19,800 shares of the biotechnology company’s stock valued at $168,000 after acquiring an additional 3,500 shares during the last quarter. 82.03% of the stock is currently owned by institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).

Recommended Story: Dividend Aristocrat Index

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.